Cellular interactions in vascular growth and differentiation

International Review of Cytology

Volumn 204, Issue , 2001, Pages 1-48

  Nguyen, Louis L ^a,b   D’amore, Patricia A ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Cell cell interaction; Development; Vasculogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ANGIOGENESIS; BLOOD FLOW; CARDIOVASCULAR SYSTEM; CELL COMMUNICATION; CELL INTERACTION; CELL MEMBRANE PERMEABILITY; EXTRACELLULAR MATRIX; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TISSUE GROWTH;

MAMMALIA;

EID: 0035120643     PISSN: 00747696     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0074-7696(01)04002-5     Document Type: Article

References (247)

1. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells
2. Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor
3. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
4. Vascular endothelial cadherin (VE-Cadherin): Cloning and role in endothelial cell-cell adhesion
5. Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation
6. Induction and maintenance of increased VEGF protein by chronic motor nerve stimulation in skeletal muscle
7. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle
8. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells
9. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization
10. VE-cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels
11. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent
12. Human microvascular endothelial cells express receptors for platelet-derived growth factor
13. Phase I trial of recombinant platelet factor 4(rPF4) in patients with advanced colorectal carcinoma
14. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
15. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
16. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo
17. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis
18. Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing GO-G1 transition
19. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation
20. Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system
21. Functional properties of human vascular endothelial cadherin (7B4/Cadherin-5), an endothelium-specific cadherin
22. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
23. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen
24. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing
25. 3 as a heterotypic ligand for CD31/PECAM-1
26. MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization
27. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells
28. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
29. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
30. Occurrence and distribution of matrix metalloproteinases-2-immunoreactivity in human embryonic tissues
31. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding
32. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors
33. Intracerebral tumor associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VGEF I89
34. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
35. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation
36. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line
37. Regulation of vascular connexin 43 gene expression by mechanical loads
38. Thalidomide is an inhibitor of angiogenesis
39. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion
40. Isolation of angiopoietin-1 a ligand for the Tie2 receptor, by secretion-trap expression cloning
41. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
42. Control of integrin expression by extracellular matrix
43. Involvement of endothelial PECAM-1/CD31 in angiogenesis
44. Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro
45. Defective haematopoesis and vasculogenesis in transforming growth factor β 1 knock out mice
46. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
47. Vascularization of the mouse embryo: A study of flk-1, tek, tie, and vascular endothelial growth factor expression during development
48. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo
49. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
50. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors
51. Tumors: Wounds that do not heal. Similarity between tumor stroma generation and wound healing
52. Fibrin containing gels induce angiogenesis: Implications for tumor stroma generation and wound healing
53. Vascular endothelial growth factor induces endothelial fenestrations in vitro
54. Junctional complexes in various epithelia
55. VEGF-induced permeability increase is mediated by caveolae
56. Molecular and biological properties of vascular endothelial growth factor
57. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
58. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
59. Aortic smooth muscle cells express and secrete vascular endothelial growth factor
60. VEGF induces cardiovascular malformation and embryonic lethality
61. Presence of a growth-stimulating factor in serum following primary tumor removal in mice
62. Induction of vasculogenesis and hematopoiesis in vitro
63. Angiogenesis in cancer, vascular, rheumatoid, and other disease
64. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
65. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis
66. Definition of two angiogenic pathways by distinct alpha v integrins
67. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases
68. Defective oligodendrocyte development and severe hypomyelination in PDGF-A knock-out mice
69. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
70. Clandin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin
71. Occludin: A novel integral membrane protein localizing at tight junctions
72. Connexin 43 is highly localized to sites of disturbed flow in rat aortic endothelium but connexin 37 and connexin 40 are more uniformly distributed
73. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
74. 3: A new prognostic indicator in breast cancer
75. Defects in mesoderm, neural tube, and vascular development in mouse embryos lacking fibronectin
76. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta expression determines growth response to angiotensin II
77. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein
78. Paracrine expression of a native soluble vascular endothelial growth factor receoptor inhibits tumor growth, metastasis, and mortality rate
79. A tumor supressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
80. The inhibition of tumor growth by tumor mass
81. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculostellate cells
82. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
83. The spatial distribution and relative abundance of gap-junctional connexin 40 and connexin 43 correlate to functional properties of components of the cardiac atrioventricular conduction system
84. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis
85. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin
86. Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1
87. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4
88. An antiphage agent isolated from Aspergillus species
89. Expression and regulation of vascular endothelial growth factor in osteoblasts
90. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin
91. Endothelin 1: Mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells
92. Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenic processes of chicken embryos
93. Expression of N-cadherin adhesion molecules associated with early morphogenic events in chick development
94. Neuropilin is a receptor for the axonal chemorepellent semaphorin III
95. Role of transforming growth factor-beta in the development of the mouse embryo
96. TGF-B signalling from cell membrane to nucleus through SMAD proteins
97. Differential expression of platelet-derived growth factor alpha- and beta-receptors on fat-storing cells and endothelial cells of rat liver
98. Heparin-hinding EGF-like growth factor stimulation of smooth muscle cell migration: Dependence on interactions with cell surface heparan sulfate
99. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
100. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenests in mice
101. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact
102. PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate
103. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
104. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
105. Cell-cell interactions in early embryogenesis: A molecular approach to the role of calcium
106. Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures
107. Cell-matrix interactions in gland development in the lung
108. Synthetic analogues of fumagillin that inhibit angiogenesis and supress tumor growth
109. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-β1
110. Astrocytic contributions to blood-brain barrier (BBB) formation by endothelial cells: A possible use of aortic endothelial cell for in vitro BBB model
111. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
112. Proteolytic processing regulates receptor specificity and activity of VEGF-C
113. Flk-1 expression defines a population of early embryonic hematopoietic precursors
114. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas
115. A requirement for neuropilin-1 in embryonic vessel development
116. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
117. Identification of a natural soluble form of the vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR
118. Identification of two further gap-junctional proteins, connexin40 and connexin45, in human myometrial smooth muscle cells at term
119. The treatment of amebiasis with fumagillin
120. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs
121. Neuropilin-semaphorin II/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice
122. Vascular endothelial growth factor and its receptors
123. Angiopoietin-1 induces sprouting angiogenesis in vitro
124. Platelets as a source of fibroblast growth-promoting activity
125. Neuropilin is a semaphorin III receptor
126. Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization
127. The mouse tie receptor tyrosine kinase gene: Expression during embryonic angiogenesis
128. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent
129. A comparative study of the expression patterns for VEGF, VEGF-B/VRF and VEGF-C in the developing and adult mouse
130. The molecular organization of endothelial cell to cell junctions: Differential association of plakoglobin, β-catenin, and α-catenin with vascular endothelial cadherin (VE-cadherin)
131. Gap junction messenger RNA expression by vascular wall cells
132. Differential regulation of connexin 43 and connexin 37 in endothelial cells by cell density, growth, and TGF-beta1
133. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells
134. Vascular endothelial growth factor is a secreted angiogenic mitogen
135. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities
136. Defective angiogenesis in mice lacking endoglin
137. A role for fibronectin in the migration of avian precardial cells I. Dose-dependent effects of fibronectin antibody
138. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
139. Expression of platelet-derived growth factor ligands and receptors by rat aortic endothelium in vivo
140. Dye tracers define differential endothelial and smooth muscle coupling patterns within the ateriolar wall
141. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
142. Embryonic lethal mutation in mouse collagen I gene causes rupture of blood vessels and is associated with erythropoietic and mesenchymal cell death
143. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors
144. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus
145. Inhibition of angiogenesis by recombinant platelet factor-4 and related peptides
146. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1
147. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor
148. New anti-angiogenesis agents: Review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12
149. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
150. Transforming growth factor-alpha. A model for membrane-anchored growth factors
151. The transforming growth factor-β family
152. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hemoatopoietic cells and exhibiting close genetic linkage to c-kit
153. Thalidomide and congenital abnormalities
154. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (flt-1) receptor tyrosine kinases
155. Neuropilin-1 is a placenta growth factor-2 receptor
156. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
157. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
158. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors
159. Shear stress increases heparin-binding epidermal growth factor-like growth factor mRNA levels in human vascular endothelial cells
160. Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix
161. Troponin I is present in human cartilage and inhibits angiogenesis
162. Assembly of fibronectin into extracellular matrix
163. PECAM-1 is required for transendothelial migration of leukocytes
164. Mouse Co118a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones
165. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
166. Direct transfer of transforming growth factor beta I gene into arteries stimulates fibrocellular hyperplasia
167. Expression of collagenase and IL-1 alpha in developing rat hearts
168. Chemotaxis under agarose: A new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes
169. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall
170. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?
171. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro
172. Rat aortic smooth muscle cells become pericytes during angiogenesis in vitro
173. Expression of transforming growth factor-beta is increased in human vascular restenosis lesions
174. + cells at a divergent point of endothelial and hemopoietic lineages
175. A novel cadherin cell adhesion molecule: Its expression patterns associated with implantation and organogenesis of mouse embryos
176. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
177. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells
178. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
179. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
180. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
181. Angiostatin induces and sustains dormancy of human primary tumors in mice
182. Angiostatin: A novel angiogenesis inhibitor that mediates the supression of metastases by a Lewis lung carcinoma
183. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
184. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2
185. TGF-beta receptor type II deficiency results in defects of yolk sac hematopiesis and vasculogenesis
186. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells
187. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization
188. Biphasic effect of transforming growth factor β1 on in vitro angiogenesis
189. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization
190. 3 integrin involved in adhesion of leukocytes to endothelium
191. Vascular endothelial growth factor
192. Isolation and characterization of a vascular endothelial mitogen produced by AT-20 cells
193. The receptor tyrosine kinase tie is required for integrity and survival of vascular endothelial cells
194. Cardiac malformation in neonatal mice lack connexin43
195. TGF-β: Structure, function, and formation
196. Increased microvascular permeability and endothelial fenestration induced by Vascular endothelial growth factor/vascular permeability factor, and host microenvironment
197. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro
198. Caveolin, a protein component of caveolae membrane coats
199. 3-mediated tissue interaction during embryonic heart development
200. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2
201. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
202. Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and the spontaneous migration of Vascular endothelial cells
203. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system
204. The in vivo activity of vascular endothelial growth factor isoforms in the avian embryo
205. Interaction of serum proteins with lung endothelial clycocalyx: Its effect on endothelial permeability
206. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
207. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
208. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human nonsmall cell lung cancer tumors: Single agent and combination chemotherapy studies
209. Growth inhibition of marine melanoma and human colon carcinoma by recombinant human platelet factor 4
210. The mouse gene for vascular endothelial growth factor
211. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interferring with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway
212. Permeability of muscle capillaries to small heme-peptides. Evidence for the existence of patent transendothelial channels
213. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
214. Rat brain capillary endothelial cells express functional PDGF B-type receptors
215. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain
216. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
217. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice
218. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites
219. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential
220. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia
221. Identification of ZO-1: A high molecular weight polypeptide associated with the fight junction (zona occludens) in a variety of epithelia
222. 3 antagonist
223. Human skin collagenase: Isolation of precursor and active forms from both fibroblast and organ cultures
224. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
225. Increased vascularization in mice overexpressing angiopoietin-1
226. The A5 antigen, a candidate for the neuronal recognition molecule, has homologies to complement components and coagulation factors
227. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis
228. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin
229. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
230. Expression of transforming growth factor-β 1 in specific cells and tissues of adult and neonatal mice
231. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages
232. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer
233. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity
234. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans
235. Occludin confers adhesiveness when expressed in fibroblasts
236. Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation
237. Expression and distribution of cell adhesion molecule uvomorulin in mouse preimplantation embryos
238. Assignment of the vascular endothelial growth factor gene to the human chromosome 6p21.3
239. Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies
240. Different signal transduction properties of KDR adn Flt1, two receptors for vascular endothelial growth factor
241. Embryonic stem cell-derived cystic embryoid bodies form vascular channels: An in vitro model of blood vessel development
242. The embryoid body as a novel in vitro assay system for antiangiogenic agents
243. A platelet factor stimulating human normal glial cells
244. The tight junction protein ZO-1 is homologous to the Drosophila discs-large tumor supressor protein of septate junctions
245. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D
246. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery
247. VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo